Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given an average rating of “Moderate Buy” by the twelve ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $33.5909.

Several analysts recently issued reports on the stock. TD Cowen upped their price objective on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Citigroup raised their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Finally, Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. The trade was a 11.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the sale, the director owned 13,701,546 shares of the company’s stock, valued at $473,388,414.30. The trade was a 5.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,359,225 shares of company stock valued at $77,401,516 in the last three months. 10.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. grew its holdings in Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares during the period. Allworth Financial LP grew its holdings in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the period. Kestra Advisory Services LLC bought a new stake in shares of Roivant Sciences in the 4th quarter valued at $47,000. Parallel Advisors LLC increased its position in shares of Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its stake in Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after buying an additional 2,665 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $35.13 on Monday. The firm has a market cap of $25.27 billion, a price-to-earnings ratio of -58.55 and a beta of 1.11. The business’s 50-day simple moving average is $30.24 and its 200-day simple moving average is $27.26. Roivant Sciences has a 52 week low of $10.70 and a 52 week high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The business had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. During the same period last year, the business earned ($0.29) EPS. As a group, equities research analysts forecast that Roivant Sciences will post -1.83 earnings per share for the current year.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.